FIELD: pharmaceutics.
SUBSTANCE: present invention relates to the use of triacetyl-3-hydroxyphenyladenosine, represented by the formula (I), or its pharmaceutically acceptable salt, or a pharmaceutical composition containing them to obtain a pharmaceutical drug for the prevention or treatment of non-alcoholic fatty liver disease, where the use is aimed at reducing body weight, liver coefficient, ALT and AST levels.
EFFECT: reducing body weight, liver coefficient, ALT and AST levels.
(I)
5 cl, 7 dwg, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIACETYL-3-HYDROXYPHENYLADENOSINE FOR OBTAINING PHARMACEUTICAL PREPARATIONS FOR REDUCING THE NUMBER OF MONOCYTES CIRCULATED IN THE BLOOD | 2017 |
|
RU2795163C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SILYBIN | 2016 |
|
RU2695224C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN | 2016 |
|
RU2697523C2 |
| METHODS FOR USE OF TRIACETYL-3-HYDROXYPHENYLADENOZINE IN TREATMENT OF INFLAMMATORY PROCESSES IN VESSELS OR IMPROVEMENT OF VESSEL ENDOTHELIUM FUNCTIONS | 2017 |
|
RU2783498C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE | 2016 |
|
RU2699011C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VITAMIN E | 2016 |
|
RU2695806C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND RADIX PUERARIAE EXTRACT | 2016 |
|
RU2697670C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN, VITAMIN E AND L-CARNITINE | 2016 |
|
RU2700793C2 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 |
|
RU2498795C2 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
